OCD
52
14
17
13
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
1.9%
1 terminated out of 52 trials
92.9%
+6.3% vs benchmark
6%
3 trials in Phase 3/4
46%
6 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 13 completed trials
Clinical Trials (52)
A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
Measuring Automated Behavioral Observations & Vocal Expressions (ABOVE)
Accelerated TMS for Depression and OCD
Light Therapy for Obsessive-compulsive Disorder (OCD)
Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder
Testing Delivery Modalities of Team-Based CBT for Pediatric Anxiety in Community Health Settings.
Neuromodulation for a Novel OCD Biomarker and Treatment
How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD
Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion
Safety and Feasibility of FUS Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Treatment Refractory Obsessive Compulsive Disorder (OCD)
Testing a Transdiagnostic TMS Treatment Target
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
Paired tVNS With ERP in OCD
Locating Biomarkers in OCD Through Behavioral Tasks
Digital Coach to Support Exposure Therapy Homework for Anxious Youth
Personalized DBS for OCD Guided by Stereoencephalography Mapping
Effect of Emotion-Focused Acceptance and Commitment Therapy on Obsessive-Compulsive Disorder Symptom Severity
Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
Open-Label Psilocybin Study in Transdiagnostic Population
Neurostimulation Versus Therapy for Problems With Emotions